Universal Biosensors appoints Peter Mullin as CFO; Salesh Balak resigns as CFO, stays as advisor
UNIVERSAL BIOSENSORS INC
Appointed Peter Mullin as CFO and Finance Director effective Dec 18, 2024; will serve as principal financial and accounting officer.
First-year total remuneration package A$275,000 (base A$246,637 + superannuation); second-year increases to A$325,000.
15M options to be granted under EIP, subject to shareholder approval; vest in three tranches at exercise prices A$0.15, A$0.20, A$0.30.
Salesh Balak resigned as CFO by mutual agreement; transitions to Corporate Advisor and remains Corporate Secretary; departure not due to disagreements.
Universal Biosensors, Inc. (the “ Company ”) announced that its board of directors (the “ Board ”) appointed Peter Mullin as Chief Financial Officer and Finance Director.
Departed
Salesh Balak
Chief Financial Officer
UNIVERSAL BIOSENSORS INC
Successor
Peter Mullin
Filed
January 7, 2025, 6:59 PM ET
the Company and Salesh Balak, the Company’s Chief Financial Officer, mutually agreed that Mr. Balak will resign from his position as Chief Financial Officer at the Company.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Peter Mullin was appointed as Chief Financial Officer and Finance Director at UNIVERSAL BIOSENSORS INC.
Action
appointed
Role
Chief Financial Officer and Finance Director
Exact text from the filing
Universal Biosensors, Inc. (the “ Company ”) announced that its board of directors (the “ Board ”) appointed Peter Mullin as Chief Financial Officer and Finance Director.
Salesh Balak resigned as Chief Financial Officer at UNIVERSAL BIOSENSORS INC.
Action
resigned
Role
Chief Financial Officer
Exact text from the filing
the Company and Salesh Balak, the Company’s Chief Financial Officer, mutually agreed that Mr. Balak will resign from his position as Chief Financial Officer at the Company.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.